The Pharmaceutical Market: Russia
Market Research Report

The Pharmaceutical Market: Russia Market Research Report

THE PHARMACEUTICAL MARKET: RUSSIA - REVIEW

The Russian pharmaceutical market is the largest in Central & Eastern Europe (CEE), and accounts for two-fifths of the total CEE pharmaceutical market, due to its large economy and population. However, Russia has one of the smallest per capita pharmaceutical spending, comparable to Romania. The Russian pharmaceutical market is projected to expand at a double-digit CAGR in US dollar terms between 2011 and 2016. It will continue to be driven by import growth; imports registered a double-digit CAGR between 2006 and 2010. In fact, a heavy reliance on imports has resulted from the lack of locally-manufactured innovative pharmaceuticals. A strategy for encouraging growth in the Russian pharmaceutical industry for the period up to 2020 envisages the government helping local producers to cover the costs of the R&D that is required to boost production of innovative pharmaceuticals.

A number of agreements have been made between Russian and foreign companies that will benefit the domestic market. AstraZeneca plans to establish a Predictive Science Centre in St Petersburg in 2012. Other developments include a joint-venture between India's Aurobindo Pharma and Russia's OJSC Diod in September 2011; an investment by Rusnano in Cleveland BioLabs' new subsidiary, Panacela Labs, in September 2011; the launch of Pro Bono Bio, developed by Celtic Pharma Holdings in September 2011; an investment agreement signed by Teva Pharmaceutical Industries for the construction of a manufacturing facility in September 2011; a licensing agreement between Norgine and Nycomed in August 2011; a collaboration between Pfizer and ChemRar High Technology Centre to explore innovative drugs in June 2011; and the construction of a pharmaceutical manufacturing plant in St Petersburg by Novartis in June 2011.

The Russian pharmaceutical market is dominated by generic products. Over the last decade, there has been a shift in demand from cheap, locally-produced generics to more expensive, branded generics of foreign origin. Branded generics are popular in Russia for historical reasons. They were largely the only pharmaceuticals available in the former USSR and both patients and doctors remain loyal to well-established brands. Furthermore, the traditionally high level of self-medication within the population has encouraged companies to produce pharmaceuticals with recognisable names. However, generics may eventually lose market share to branded pharmaceuticals if the government's plan to vastly increase the number of locally-manufactured innovative drugs is successful.

ENHANCED STRATEGIC INTELLIGENCE

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

• Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
• Specialised intelligence on OTCs, generics, biologics and biosimilars.
• Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
• A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
• The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

• Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
• Specialised intelligence on OTCs, generics, biologics and biosimilars.
• Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
• A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
• The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

• EXECUTIVE SUMMARY
  • Snapshot: Strategic Espicom Analysis
  • Snapshot: Key Data Projections
• MACROENVIRONMENT
• POLITICAL
• ECONOMIC
  • Projections
  • LEGAL
• DEMOGRAPHIC
  • Projections
  • Demographic Indicators
  • Births
  • Deaths
  • Infant Deaths
  • Life Expectancy at Birth
• EPIDEMIOLOGY
• DISEASE BURDEN
  • Leading Causes of Mortality
• DISEASE PREVALENCE
  • Communicable Diseases
  • HIV/AIDS
  • Non-Communicable Diseases
• HEALTHCARE - ACCOMPANYING HEALTH STATISTICS
• ORGANISATION
  • Fundamentals of Protection of Public Health in the Russian Federation Bill
  • Regional Healthcare Modernisation Programme
  • Concept for the Development of the Healthcare Sector until 2020
  • National Health Project
• EXPENDITURE
  • Projections
  • Social Security
  • New Legislation 'Concerning the Obligatory Medical Insurance'
• INFRASTRUCTURE
  • Hospital Infrastructure
  • Outpatient Infrastructure
• SERVICES
  • Hospital Inpatient Services
  • Outpatient Services
• WORKFORCE
  • Projections
  • Physicians
• REGULATORY AFFAIRS
• NATIONAL AUTHORITY
• REGULATORY DEVELOPMENTS
• MARKETING REGISTRATION
• IMPORT REGULATIONS
• PROMOTION
  • Advertising
• PRICING & REIMBURSEMENT
• PRICING
  • New Methods for Setting Retail Prices of Medicines Explored
  • Registration of Maximum Prices
  • Price Freezes
• REIMBURSEMENT
  • Procurement of Pharmaceuticals for the DLO
  • Future of the DLO
  • Subsidising of Prescription Medicines
• List of Vitally Important Drugs for 2011
• DISTRIBUTION CHANNELS
• DRUG WHOLESALING
  • Leading Wholesalers
  • Protek
  • Shreya Corporation
• SIA International
• DRUG RETAILING
  • Leading Pharmacy Chains
  • Pharmacy Chain 36.6
  • Rigla
• MARKET ANALYSIS
  • SIZE
  • Projections
  • Historical Figures
  • Current Structure
  • Pharmacy Market
  • Hospital Market
• PRODUCT DEVELOPMENT
  • Clinical Trials
• MANUFACTURING
• Government Programme for the Development of the Pharmaceutical Industry
  • TRADE
  • Exports
  • Imports
• Balance of Trade
• COMPETITION
• TRADE ASSOCIATION
  • AIPM
• TRADE FAIRS
  • Hospital
  • Pharmtech 2012
• COMPANY INTELLIGENCE
  • Foreign Producers
  • KRKA
  • Sanofi
• STADA CIS
  • Local Producers
  • Akrikhin
  • JSC Farmacon
  • Pharmstandard
  • Pharm-Sintez
  • Valenta
  • Veropharm
  • Yugrafarm
  • Competitive Strategies
  • AstraZeneca
  • Aurospharma Company
  • Chemical Diversity Research Institute (CDRI)
  • Dr Reddy's
  • Incuron
• JB Chemicals & Pharmaceuticals
  • Maxwell Biotech Group
  • Neuralstem
  • Novartis
  • Nycomed
  • Panacela Labs
• Pfizer
  • Pro Bono Bio
• Ranbaxy
  • Teva
• OTC PHARMACEUTICALS
• MARKET SIZE
• COMPETITION
• GENERIC PHARMACEUTICALS
• MARKET SIZE
• COMPETITION
• BIOLOGICS & BIOSIMILARS
• COMPETITION
  • Binnopharm
  • Biocad
  • Generium
  • Pushchino Scientific Centre
• CONCLUSIONS: OPPORTUNITIES & CHALLENGES
  • Strategic Espicom Analysis
• MACROENVIRONMENT
• EPIDEMIOLOGY
• HEALTHCARE
• REGULATORY AFFAIRS
• PRICING & REIMBURSEMENT
• DISTRIBUTION CHANNELS
  • MARKET
• COMPETITION
• OTC PHARMACEUTICALS
• GENERIC PHARMACEUTICALS
• BIOLOGICS & BIOSIMILARS
  • Radar Analysis
  • SWOT Analysis
• DIRECTORY
• GOVERNMENT ORGANISATIONS
• PHARMACEUTICAL PRODUCERS
  • Foreign Pharmaceutical Producers
  • Local Pharmaceutical Producers
  • Biologic & Biosimilar Producers
• TRADE ASSOCIATIONS
• List of tabLes
  • Espicom Analysis of the Pharmaceutical Market, 2011
  • Key Data Projections, 2011-2016
  • Political Landscape, 2011
  • Regional Ranking of Projected Economies, 2016
  • Projected Economy, 2011-2016
  • Regional Ranking of Projected Demographics, 2016
  • Projected Demographics, 2011-2016
  • Demographic Indicators, 2001-2009
  • Leading Causes of Death, 2007-2009
  • HIV & AIDS Trends, 1986-2006
  • Incidence of Morbidity by Diagnosis, 2007-2009 (000s)
  • Regional Ranking of Projected Health Expenditure, 2016
  • Projected Health Expenditure, 2011-2016
  • Total Hospitals & Beds, 1990-2009
  • Outpatient Care Facilities, 1995-2008
  • Public Inpatient Activity, 2002-2008
  • Public Hospital Discharges by Group of Diseases, 2005-2008
  • Day Surgery Discharges by Group of Diseases, 2005-2008
  • Regional Ranking of Projected Physicians, 2016
  • Projected Physicians, 2011-2016
  • Pharmacy Chain 36.6 Financial Results, 2002-2010 (US$ Millions)
  • Regional Ranking of Projected Pharmaceutical Markets at Retail Prices, 2016
  • Projected Pharmaceutical Market at Retail Prices, 2011-2016
  • Historical Pharmaceutical Market at Retail Prices, 1995-2010
  • Pharmacy Sales at Retail Prices, 2003-2011
  • Pharmacy Sales at Wholesale Prices, 2003-2011
• Pharmacy Sales Volume, 2003-2011
  • Moscow City Pharmacy Sales at Retail Prices, 2004-2011
  • Moscow City Pharmacy Sales at Wholesale Prices, 2004-2011
  • Moscow City Pharmacy Sales Volume, 2004-2011
  • St Petersburg City Pharmacy Sales at Retail Prices, 2004-2011
  • St Petersburg City Pharmacy Sales at Wholesale Prices, 2004-2011
  • St Petersburg City Pharmacy Sales Volume, 2004-2011
  • Hospital Purchases at Wholesale Prices, 2003-2011
  • Hospital Purchases Volume, 2003-2011
  • Moscow City Hospital Purchases at Wholesale Prices, 2004-2011
  • Moscow City Hospital Purchases Volume, 2004-2011
  • St Petersburg City Hospital Purchases at Wholesale Prices, 2004-2011
  • St Petersburg City Hospital Purchases Volume, 2004-2011
  • APS Sales at Wholesale Prices, 2006-2011
  • APS Sales Volume, 2006-2011
  • Production Value at Manufacturers' Prices, 2004-2011
  • Pharmaceutical Exports by Category, 1995-2010 (US$000s)
  • Pharmaceutical Exports by Country/Region, 2010 (US$000s)
  • Pharmaceutical Imports by Category, 1995-2010 (US$000s)
  • Imports of Raw Materials by Country/Region, 2010 (US$000s)
  • Imports of Antisera & Vaccines by Country/Region, 2010 (US$000s)
  • Imports of Medicaments by Country/Region, 2010 (US$000s)
  • Balance of Pharmaceutical Trade, 1995-2010 (US$000s)
  • AIPM Members, 2011
  • Top Pharmaceutical Companies by Sales, 2009-2010 (%)
  • Pharmstandard Financial Results, 2004-2010 (R Millions)
  • Pharmstandard Pharmaceutical Sales, 2007-2010 (R Millions)
• Pharmstandard Top 10 OTCs, 2009
  • Pharmstandard Production by Facility, 2009-2010
  • Top Ten Manufacturers, Trade Names and ATG Groups in the OTC Market, 2009
  • Espicom Analysis of the Pharmaceutical Market, 2011
  • SWOT Analysis of the Pharmaceutical Market, 2011
• List of Charts
  • Regional Comparison of Top 6 Projected Pharmaceutical Markets at Retail Prices, 2016
  • Regional Comparison of Projected Pharmaceutical Market Share at Retail Prices, 2016
  • Historical Pharmaceutical Market at Retail Prices, 1995-2010
  • Pharmaceutical Exports, 1995-2010 (US$ Millions)
  • Pharmaceutical Imports, 1995-2010 (US$ Millions)
  • Pharmaceutical Imports by Country/Region, 2010 (%)
  • Balance of Pharmaceutical Trade, 1995-2010 (US$ Millions)
  • Radar Graph of the Pharmaceutical Market, 2011